MINNEAPOLIS, MN — The SYMPLICITY HTN-3 trial, a phase 3 study testing catheter-based renal denervation for the treatment of resistant hypertension, failed to achieve its primary efficacy end point, ...

RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...

CHICAGO — The addition of lorundrostat, an investigational drug, to the treatment regimen of people with well-treated but uncontrolled and resistant hypertension could be beneficial, new data show.

Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat safely lowered 24-hour systolic BP compared with placebo in a phase 2 trial. A ...

CHICAGO, IL—In the expanded SPYRAL HTN-ON MED trial, renal denervation with the Symplicity Spyral multielectrode catheter (Medtronic) failed to meet its primary endpoint in terms of blood ...

DUBLIN and CHICAGO, Nov. 7, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the six-month results from the full cohort of the SPYRAL HTN-ON MED ...

It's almost impossible to keep up with what things mean on TikTok, which is mostly thanks to the users who come up with phrases, memes, and acronyms almost daily. And when one sticks, you'd better be ...

WASHINGTON, DC—Despite an initial hint to the contrary, Black patients with uncontrolled hypertension seem to benefit from renal denervation to the same extent as non-Black patients by 3 years, ...

Mineralys Therapeutics announced the positive results of its Launch-HTN trial, the largest study of an aldosterone synthase inhibitor for patients with uncontrolled or treatment-resistant hypertension ...

RADNOR, Pa., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and ...